Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications Geneva (Switzerland), January 20, 2026 – ...
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief ...
Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office strengthens patent protection of ATP-R13 Progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results